Publication in Cancer Research Demonstrates Crescendo Biologics’ Humabody® VH Therapeutics Outperform Conventional Antibodies in Vivo

Business Wire

Published

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted, T cell enhancing therapeutics, announces the publication of a paper that demonstrates greater tissue penetration and in vivo efficacy of Humabody® VH therapeutics compared to conventional antibody formats, in the scientific journal Cancer Research a journal of the American Association for Cancer Research. The full paper by Nessler et al can be accessed online HERE. The study run by D

Full Article